奥沙利铂联合醛氢叶酸和5氟脲嘧啶用于进展期胃癌术后辅助化疗的临床观察

Clinical Observation of Combined Oxaliplatin with Leucovorin and 5-Fiuorouracil in Advanced Gastric Caricinoma

目的 :观察奥沙利铂、醛氢叶酸和 5 氟脲嘧啶治疗进展期胃癌的疗效和毒性。方法 :5 0例选择性D3 清扫术后的Ⅲ期胃癌患者随机分为OLF治疗组 (L OHP 130mg/m2 ,d1;LV 10 0mg/m2 ,dl～ 5 ;5 FU 5 0 0mg/m2 ,d1～ 5 )和FLP对照组 (DDP 2 0mg/m2 ,d1～ 5 :LV 10 0mg/m2 ,d1～ 5 ;5 Fu 5 0 0mg/m2 ,d1～ 5 )。以上方案均为三周重复。结果 :OLF治疗组和FLP对照组的 1,3年总生存率比较分别为 84 0 %vs72 0 %和 76 2 %vs 5 5 6 % ,无异著差异。OLF治疗组和FLP对照组的 1、3年无进展生存率比较分别为 76 0 %vs 4 4 0 %和 6 6 7%vs 2 7 8% ,均有显著差异。结论 :奥沙利铂联合醛氢叶酸和 5 氟脲嘧啶是Ⅲ期胃癌选择性D3 清扫术后较为理想的辅助化疗模式。

Objective:To survey the clinical efficacy and toxicity of advanced gastric carcinoma using OLF (L-OHP/LV/5-FU) regimen or FLP (DDP/LV/5-FU) regimen.Methods:50 cases of gastric cancinoma in stage Ⅲ operated by D3 gastrectomy were randomized into two groups. 25 cases were treated with OLF regimen (L-OHP 130mg/m 2/dl, LV 100mg/m 2/dl～5, 5-FU 500mg/m 2/dl～5) and the other 25 cases were treated with FLP regimen (DDP 20mg/m 2/d1～5, LV 100mg/m 2/dl～5, 5-FU 500mg/m 2/dl～5). All repeated every 3 weeks.Results:The 1-year and 3-year survival rates of the two groups are 84.0% vs 72.0% (P>0.05) and 76.2% vs 55.6% (P>0.05). The 1-year and 3-year disease-free survival rates of the two groups are 76.0% vs 44.0% (P<0.05) and 66.7% vs 27.8% (P<0.05).Conclusion:These results showed that OLF regimen may be promising for treating advanced gastric carcinoma and it is worthy of further clinical trial.